Wednesday, July 8, 2026

Patent intelligence · US

US 11718852

Non-liposomal systems for nucleic acid delivery

granted A61KA61K31/7088A61K31/7105A61K31/712
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 56
Patent details — US 11718852
Jurisdiction
US
Status
granted
Grant date
Aug 8, 2023
Expiration
Aug 3, 2043
Claims
32
CPC classes
A61K, A61K31/7088, A61K31/7105, A61K31/712
View on Google Patents ↗

Quick answer

US 11718852 (Non-liposomal systems for nucleic acid delivery) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted Aug 8, 2023. Expires Aug 3, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
32
CPC classes
A61K, A61K31/7088, A61K31/7105, A61K31/712, A61K31/713, A61K47/14

More from ARBUTUS BIOPHARMA CORPORATION

Related pharmaceutical patents in our USPTO index.

  1. US 12357705

    Negatively charged peg-lipid conjugates

    ARBUTUS BIOPHARMA CORPORATION · Expires Jul 10, 2045

    granted
  2. US 12350383

    Cationic lipids containing silicon

    ARBUTUS BIOPHARMA CORPORATION · Expires Jul 3, 2045

    granted
  3. US 12251470

    Lipid nanoparticle formulations

    ARBUTUS BIOPHARMA CORPORATION · Expires Mar 13, 2045

    granted
  4. US 12129467

    Non-liposomal systems for nucleic acid delivery

    ARBUTUS BIOPHARMA CORPORATION · Expires Oct 24, 2044

    granted
  5. US 12083118

    Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same

    ARBUTUS BIOPHARMA CORPORATION · Expires Sep 5, 2044

    granted
  6. US 12043833

    Targeted compositions

    ARBUTUS BIOPHARMA CORPORATION · Expires Jul 18, 2044

    granted
  7. US 12042541

    Lipids and compositions for the delivery of therapeutics

    ARBUTUS BIOPHARMA CORPORATION · Expires Jul 18, 2044

    granted
  8. US 12023383

    Lipid compositions

    ARBUTUS BIOPHARMA CORPORATION · Expires Jun 27, 2044

    granted

Frequently asked questions

What is US patent 11718852?

US 11718852 (Non-liposomal systems for nucleic acid delivery) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted Aug 8, 2023. Expires Aug 3, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11718852?

ARBUTUS BIOPHARMA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 56 pharmaceutical patents for this assignee.

When does US 11718852 expire?

Our index shows an expiration date of Aug 3, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.